Videos

Judd W. Moul, MD, FACS: Safety and Tolerability Issues

June 18th 2015

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

June 18th 2015

Metastatic Prostate Cancer: Case 2

June 18th 2015

Metastatic Prostate Cancer

E. David Crawford, MD: Chemotherapy Consideration

June 18th 2015

E. David Crawford, MD: Influences on Treatment Options

June 18th 2015

E. David Crawford, MD: Safety and Tolerability Issues

June 18th 2015

E. David Crawford, MD: Options to Control Recurrent Metastatic Disease

June 18th 2015

Judd W. Moul, MD, FACS: Chemotherapy Consideration

June 18th 2015

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

June 18th 2015

Metastatic Prostate Cancer: Case 1

June 18th 2015

Metastatic Prostate Cancer

Pierre Gholam, MD: Treatment Selection

June 18th 2015

Pierre Gholam, MD: Alcohol Abuse Impact on Treatment

June 18th 2015

Nicholas Nissen, MD: Treatment Selection

June 18th 2015

Nicholas Nissen, MD: Monitoring of Patient

June 18th 2015

Richard Finn, MD: Treatment Selection

June 18th 2015

Richard Finn, MD: Most Appropriate Treatment

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 3

June 18th 2015

Unresectable Hepatocellular Carcinoma

Pierre Gholam, MD: Potential for Systemic Therapy

June 18th 2015

Pierre Gholam, MD: Recommended Screening

June 18th 2015

Nicholas Nissen, MD: Potential for Systemic Therapy

June 18th 2015

Nicholas Nissen, MD: Estimate of TACE Procedures

June 18th 2015

Richard Finn, MD: Potential for Systemic Therapy

June 18th 2015

Richard Finn, MD: Significance of Baseline AFP Levels

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 2

June 18th 2015

Unresectable Hepatocellular Carcinoma

Pierre Gholam, MD: Consideration of Different Modalities

June 18th 2015

Pierre Gholam, MD: Next Steps for Jose

June 18th 2015

Nicholas Nissen, MD: Next Steps for Jose

June 18th 2015

Nicholas Nissen, MD: Consideration of Different Modalities

June 18th 2015

Richard Finn, MD: Next Steps for Jose

June 18th 2015

Richard Finn, MD: Consideration of Different Modalities

June 18th 2015

Videos

Judd W. Moul, MD, FACS: Safety and Tolerability Issues

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

Metastatic Prostate Cancer: Case 2

E. David Crawford, MD: Chemotherapy Consideration

E. David Crawford, MD: Influences on Treatment Options

E. David Crawford, MD: Safety and Tolerability Issues

E. David Crawford, MD: Options to Control Recurrent Metastatic Disease

Judd W. Moul, MD, FACS: Chemotherapy Consideration

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

Metastatic Prostate Cancer: Case 1

Pierre Gholam, MD: Treatment Selection

Pierre Gholam, MD: Alcohol Abuse Impact on Treatment

Nicholas Nissen, MD: Treatment Selection

Nicholas Nissen, MD: Monitoring of Patient

Richard Finn, MD: Treatment Selection

Richard Finn, MD: Most Appropriate Treatment

Unresectable Hepatocellular Carcinoma: case 3

Pierre Gholam, MD: Potential for Systemic Therapy

Pierre Gholam, MD: Recommended Screening

Nicholas Nissen, MD: Potential for Systemic Therapy

Nicholas Nissen, MD: Estimate of TACE Procedures

Richard Finn, MD: Potential for Systemic Therapy

Richard Finn, MD: Significance of Baseline AFP Levels

Unresectable Hepatocellular Carcinoma: case 2

Pierre Gholam, MD: Consideration of Different Modalities

Pierre Gholam, MD: Next Steps for Jose

Nicholas Nissen, MD: Next Steps for Jose

Nicholas Nissen, MD: Consideration of Different Modalities

Richard Finn, MD: Next Steps for Jose

Richard Finn, MD: Consideration of Different Modalities

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Sacituzumab Govitecan: Elevating Quality of Life in First-Line TNBC

Dr Mayer on Giredestrant's Success in Early Breast Cancer

Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD

PLT012 Receives IND Clearance from FDA for Solid Tumors

Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC